Table 4. Cox proportional hazard regression models for univariate survival.
| Risk Factor | Median Survival (95% CI), months | Hazard Ratio (95% CI) | P Value |
|---|---|---|---|
| Sex, Male vs Female | 27.4 (20.6–31.7) vs 39.8 (33.5–45.5) | 1.56 (1.21–2.00) | <0.001 |
| Age, > = 70 vs <70 | 29.0 (19.5–36.5) vs 36.3 (31.4–42.9) | 1.41 (1.08–1.85) | 0.012 |
| Smoking Status, Medium + Heavy vs Never + Light |
|||
| 25.7 (22.1–33.3) vs 39.5 (32.9–45.5) | 1.42 (1.10–1.83) | 0.006 | |
| EGFR (Actionable)ab | |||
| Positive vs Negative EGFR x time |
39 (32.6–43.8) vs 26 (22.1–32.9) | 0.46 (0.31–0.68) 1.02 (1.01–1.03) |
0.0001 0.0022 |
| ALK (Rearrangement)b | |||
| Positive vs Negative | 82.6 (82.6-NR) vs 26.6 (22.1–33.1) | 0.35 (0.17–0.68) | 0.002 |
| ROS1 (Rearrangement)b | |||
| Positive vs Negative | NR vs 26 (20.8–33.3) | - | - |
| BRAF (V600E)b | |||
| Positive vs Negative | 73.4 (11.6-NR) vs 28.0 (22.2–34.4) | 0.70 (0.26–1.91) | 0.487 |
| MET (exon 14 Splice-site/Deletion)b | |||
| Positive vs Negative | 17.2 (8.77-NR) vs 28.0 (22.2–34.4) | 0.59 (0.19–1.89) | 0.377 |
| KRAS in Actionablec | |||
| Positive vs Negative KRAS x time |
25.5 (17.6–32.9) vs 41.4 (39.3–55.0) | 2.80 (1.70–4.61) 0.98 (0.97–0.99) |
<0.0001 0.0065 |
| KRAS in Non-Actionabled | |||
| Positive vs Negative | 25.5 (17.6–32.9) vs 27.7 (22.2–42.9) | 1.06 (0.73–1.53) | 0.769 |
| TP53 in Actionablec | |||
| Positive vs Negative | 25.5 (20.6–34.9) vs 67.6 (39.5-NR) | 1.87 (1.12–3.12) | 0.017 |
| TP53 in Non-Actionabled | |||
| Positive vs Negative | 25.5 (20.6–34.9) vs 30.1 (21.6–54.0) | 1.13 (0.75–1.69) | 0.561 |
a. EGFR All patients had EGFR tested.
b. For each gene, patients carrying actionable alterations were compared with patients who were tested negative, with patients carrying actionable alterations from other genes excluded from its analysis.
c. For KRAS and TP53, patients who were tested positive with no actionable alteration were compared with patients who were tested negative but had actionable gene alterations.
d. For KRAS and TP53, patients who were tested positive were compared with patients who were tested negative and patients who had actionable gene alterations were excluded from both groups.